Similar articles for PMID: 23918734

Year	Number of Results
1997	1
1999	2
2000	2
2001	2
2002	7
2003	11
2004	10
2005	7
2006	8
2007	8
2008	10
2009	9
2010	7
2011	5
2012	6
2013	7
2014	6
2020	2
2021	11
2022	6
2023	2
2024	0

1

Radiobiologic optimization of combination radiopharmaceutical therapy applied to myeloablative treatment of non-Hodgkin lymphoma.

Hobbs RF, Wahl RL, Frey EC, Kasamon Y, Song H, Huang P, Jones RJ, Sgouros G. Hobbs RF, et al. J Nucl Med. 2013 Sep;54(9):1535-42. doi: 10.2967/jnumed.112.117952. Epub 2013 Aug 5. J Nucl Med. 2013. PMID: 23918734 Free PMC article.

2

Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.

Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, Sparks RB, Stabin MG, Witzig T, White CA. Wiseman GA, et al. J Nucl Med. 2003 Mar;44(3):465-74. J Nucl Med. 2003. PMID: 12621016 Free article. Clinical Trial.

3

Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results.

Chiesa C, Botta F, Di Betta E, Coliva A, Maccauro M, Aliberti G, Bavusi S, Devizzi L, Guidetti A, Seregni E, Gianni AM, Bombardieri E. Chiesa C, et al. Cancer Biother Radiopharm. 2007 Feb;22(1):113-20. doi: 10.1089/cbr.2007.302. Cancer Biother Radiopharm. 2007. PMID: 17627419 Clinical Trial.

4

Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (¹¹¹In)/Yttrium 90 (⁹⁰Y) Ibritumomab Tiuxetan (Zevalin^®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels.

Wahl RL, Frey EC, Jacene HA, Kahl BS, Piantadosi S, Bianco JA, Hammes RJ, Jung M, Kasecamp W, He B, Sgouros G, Flinn IW, Swinnen LJ. Wahl RL, et al. Cancers (Basel). 2021 Jun 6;13(11):2828. doi: 10.3390/cancers13112828. Cancers (Basel). 2021. PMID: 34204102 Free PMC article.

5

Dosimetry in patients with B-cell lymphoma treated with [(90)Y]ibritumomab tiuxetan or [(131)I]tositumomab.

Sjögreen-Gleisner K, Dewaraja YK, Chiesa C, Tennvall J, Lindén O, Strand SE, Ljungberg M. Sjögreen-Gleisner K, et al. Q J Nucl Med Mol Imaging. 2011 Apr;55(2):126-54. Q J Nucl Med Mol Imaging. 2011. PMID: 21386787 Review.

6

High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes.

Rajendran JG, Fisher DR, Gopal AK, Durack LD, Press OW, Eary JF. Rajendran JG, et al. J Nucl Med. 2004 Jun;45(6):1059-64. J Nucl Med. 2004. PMID: 15181141 Free article. Clinical Trial.

7

Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose.

Rajendran JG, Gopal AK, Fisher DR, Durack LD, Gooley TA, Press OW. Rajendran JG, et al. J Nucl Med. 2008 May;49(5):837-44. doi: 10.2967/jnumed.107.043190. Epub 2008 Apr 15. J Nucl Med. 2008. PMID: 18413376 Free article.

8

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, Schilder RJ, Murray JL, Saleh M, Allen RS, Grillo-López AJ, White CA. Wiseman GA, et al. Blood. 2002 Jun 15;99(12):4336-42. doi: 10.1182/blood.v99.12.4336. Blood. 2002. PMID: 12036859 Free article. Clinical Trial.

9

Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Winter JN, Inwards DJ, Spies S, Wiseman G, Patton D, Erwin W, Rademaker AW, Weitner BB, Williams SF, Tallman MS, Micallef I, Mehta J, Singhal S, Evens AM, Zimmer M, Molina A, White CA, Gordon LI. Winter JN, et al. J Clin Oncol. 2009 Apr 1;27(10):1653-9. doi: 10.1200/JCO.2008.19.2245. Epub 2009 Mar 2. J Clin Oncol. 2009. PMID: 19255322 Free PMC article. Clinical Trial.

10

Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.

Wagner HN Jr, Wiseman GA, Marcus CS, Nabi HA, Nagle CE, Fink-Bennett DM, Lamonica DM, Conti PS. Wagner HN Jr, et al. J Nucl Med. 2002 Feb;43(2):267-72. J Nucl Med. 2002. PMID: 11850494 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

119 results

Results by year